The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease.
Activities of Daily Living
Aged
Aged, 80 and over
Alzheimer Disease
/ drug therapy
Case-Control Studies
Cholinesterase Inhibitors
/ therapeutic use
Cognition
/ drug effects
Comorbidity
Cytidine Diphosphate Choline
/ therapeutic use
Female
Humans
Italy
Male
Memantine
/ administration & dosage
Retrospective Studies
Rivastigmine
/ therapeutic use
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
accepted:
27
12
2020
pubmed:
24
1
2021
medline:
23
3
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
Combined therapy of memantine or acetylcholinesterase inhibitors, with cholinergic precursors such as citicoline, can be effective in Alzheimer's disease. Indeed, they are able to increase the intrasynaptic levels of acetylcholine more than the single drug. Our aim was to evaluate the efficacy and safety of oral citicoline plus memantine plus rivastigmine in patients with Alzheimer's disease. This was a multi-centric, retrospective case-control study conducted in Italian Centers for Cognitive Impairment and Dementia on consecutive patients aged 65 years or older affected with Alzheimer's disease. Overall, 104 patients were recruited (27% male, mean age 76.04 ± 4.92 years); 41 (39.42%) treated with citicolin 1000 mg/day given orally + memantine + rivastigmine (Cases) and 63 (60.58%) treated with memantine + rivastigmine (Controls). At baseline (T0), month 6 (T1) and month 12 (T2), cognitive functions were assessed by the Mini Mental State Examination (MMSE), functional dependence by basal Activities (ADL) and Instrumental Activities of Daily Living (IADL), comorbidity by the Cumulative Illness Rating Scale (CIRS), mood by the Geriatric Depression Scale (GDS), and behavioural disturbances by the Neuropsychiatric Inventory (NPI). Adverse events were reported during the study. The difference in MMSE score was not significant when comparing the two groups at T0, T1 or T2. However, in the case group, the MMSE total score showed a statistically significant difference at T0 versus T1 (13.63 ± 2.46 vs. 14.17 ± 2.24; p = 0.008), and at T0 versus T2 (13.63 ± 2.46 vs. 14.32 ± 2.53; p = 0.002). In the control group, no statistical differences were found at baseline (T0), T1 and T2. ADL, IADL, GDS and NPI total score did not improve during the study in either the case or the control group. In our study we observed absence of a statistically significant difference between case and control groups for the MMSE total scores. However, in the case group in the MMSE total scores, there was a statistically significant increase between the baseline and the end of the study.
Identifiants
pubmed: 33484469
doi: 10.1007/s40261-020-00996-2
pii: 10.1007/s40261-020-00996-2
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Cytidine Diphosphate Choline
536BQ2JVC7
Rivastigmine
PKI06M3IW0
Memantine
W8O17SJF3T
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-182Commentaires et corrections
Type : ErratumIn
Références
Clodomiro A, Gareri P, Puccio G, Frangipane F, Lacava R, Castagna A, Manfredi GL, Colao R, Bruni AC. Somatic comorbidities and Alzheimer’s disease treatment. NeurolSci. 2013;34(9):1581–9.
Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find ExpClinPharmacol. 1995;17(suppl B):1–54.
Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;18(2):CD000269.
Hurtado O, Lizasoain I, Moro MÁ. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke. 2011;42(suppl1):S33–5.
doi: 10.1161/STROKEAHA.110.597435
Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. ClinInterv Aging. 2015;3(10):1421–9. https://doi.org/10.2147/CIA.S87886 .
doi: 10.2147/CIA.S87886
Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD study: CITIcoline plus RIVAstigmine in elderly patients affected with dementia study. Clin Drug Investig. 2016;36(12):1059–65.
doi: 10.1007/s40261-016-0454-3
Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F, et al. The Citicholinage study: citicoline plus cholinesterase inhibitors in aged patients affected with alzheimer’s disease study. J Alzheimer’s Dis. 2017;56:557–65.
doi: 10.3233/JAD-160808
Vincent S, Lane R. Rivastigmine in vascular dementia. IntPsychogeriatrics. 2003;15(Suppl 1):201–5.
Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. ClinTher. 1998;20(4):634–47.
Lefèvre G, Buche M, Sedek G, Maton S, Enz A, Lorch U, et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J ClinPharmacol. 2009;49:430–43.
Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5:160–70.
doi: 10.1038/nrd1958
Lipton SA. Pathologically-activated therapeutics for neuroprotection: Mechanism ofNMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8:621–5.
doi: 10.2174/138945007780618472
McAllister J, Ghosh S, Berry D, Park M, Sadeghi S, Wang KX, Parker WD, Swerdlow RH. Effects of memantine on mitochondrial function. BiochemPharmacol. 2008;75:956–64.
Folch J, Busquets B, Ettcheto M, Sanchez-Lopez E, Castro-Torres RD, et al. Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimer’s Dis. 2018;2018:1223–40. https://doi.org/10.3233/JAD-170672 .
doi: 10.3233/JAD-170672
Gareri P, Cotroneo AM, Orsitto G, Putignano S. The CITIMEM study: A pilot study. Optimizing pharmacological treatment in Dementia. Arch Gerontol Geriatrics. 2020;89:104073.
doi: 10.1016/j.archger.2020.104073
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
doi: 10.1016/0022-3956(75)90026-6
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.
doi: 10.1001/jama.1963.03060120024016
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.
doi: 10.1093/geront/9.3_Part_1.179
Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am GeriatrSoc. 1968;16(5):622–6.
doi: 10.1111/j.1532-5415.1968.tb02103.x
Rinaldi P, Mecocci P, Benedetti C, Ercolani S, Bregnocchi M, Menculini G, et al. Validation of the five-item geriatric depression scale in elderly subjects in three different settings. J Am GeriatrSoc. 2003;51(5):694–8.
doi: 10.1034/j.1600-0579.2003.00216.x
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inentory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.
doi: 10.1212/WNL.44.12.2308
Winslow B, Onysko M, Stob C. Hazlewood K Treatment of Alzheimer’s disease. Am Fam Physician. 2011;570(1404–1412):571.
Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, Scapicchio P, Senin U, Trabucchi M, Musicco M. Guidelines for the treatment ofAlzheimer’s disease from the Italian association of psichogeriatrics. Drugs Aging. 2005;2005:1–26.
Piamonte BLC, Espiritu AI, Anlacan VMM. Effects of citicoline as an adjunct treatment for Alzheimer’s disease: a systematic review. J Alzheimer’s Dis. 2020. https://doi.org/10.3233/JAD-200378 .
doi: 10.3233/JAD-200378
Gareri P, Putignano D, Castagna A, Cotroneo AM, De Palo G, Fabbo A, Forgione L, Giacummo A, Lacava R, Marino S, Simone M, Zurlo A, Putignano S. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study. J Alzheimers Dis. 2014;41(2):633–40. https://doi.org/10.3233/JAD-132735 .
doi: 10.3233/JAD-132735
pubmed: 24643135